REGN FY 2014 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$80B

FY 2014 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.8B+34.0% YoY

Gross Profit

$2.6B90.9% margin

Operating Income

$824M29.2% margin

Net Income

$348M12.3% margin

EPS (Diluted)

$2.98

Cash Flow

Operating Cash Flow

$752M

Free Cash Flow

$419M

Stock-Based Comp.

$307M

Balance Sheet

Total Assets

$3.9B

Total Liabilities

$1.3B

Stockholders' Equity

$2.5B

Cash & Equivalents

$649M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.8B	$2.1B	+34.0%
Gross Profit	$2.6B	$1.9B	+34.3%
Operating Income	$824M	$743M	+10.9%
Net Income	$348M	$424M	-18.0%